Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Public Safety topic
No spam. Unsubscribe anytime.
Presenter unveils portable detector to identify fentanyl analogs
Summary
A presenter demonstrated FADE, a roughly 10‑pound, battery‑operated detector that the presenter said can identify fentanyl and related synthetic opioid analogs — including ones not yet synthesized — in about 10 minutes using an analog‑independent approach rather than a library of known compounds.
A presenter demonstrated a portable detector called FADE that he said is designed to identify fentanyl and related synthetic‑opioid analogs, including variants that have not yet been seen, and to deliver a result in about 10 minutes.
The presenter said the device uses an analog‑independent detection method rather than relying on a library of previously identified compounds, and argued that approach is necessary because illicit manufacturers continually change chemical “recipes.” “If we crack down on the precursors for fentanyl, they go out and they find whatever they can to make these compounds,” the presenter said, using a cookie analogy to explain how chemists alter formulas.
He described FADE as about 10 pounds, battery operated and small enough to fit in any first‑responder vehicle. “Sample goes in here. You push a button — about 10 minutes later you have all of your information identifying whether or not it’s a fentanyl‑class compound on your hands,” the presenter said. He added the system requires no consumables and is intended to be inexpensive for wider deployment.
The presenter said conventional detection techniques rely on libraries of known substances — meaning an agency must have previously synthesized and cataloged a compound for it to be detected — and that FADE’s backbone‑structure approach can flag analogs that do not yet exist in those libraries. He cited an estimate that there could be roughly 4,300 possible analog compounds, presenting that number as an estimate rather than an independently verified count.
As an intended use case, the presenter explained that sampling media can be used to collect traces from a suspicious package, which is then inserted into the device’s sampling orifice and started; the unit would report whether fentanyl or a similar hazardous material is present. The presenter said the technology could help first responders identify hazards more rapidly and “save lives.”
The demonstration did not include independent validation data or third‑party test results for the device’s accuracy against a broad set of analogs, and the presenter did not give a timetable for deployment or regulatory review. The presenter’s claims and the cited estimate of analog counts are presented as his statements from the demonstration.
